Related references
Note: Only part of the references are listed.Uterine serous carcinoma
Giorgio Bogani et al.
GYNECOLOGIC ONCOLOGY (2021)
Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
Dora Cerina et al.
PATHOLOGY & ONCOLOGY RESEARCH (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Won-Chul Lee et al.
GENOME BIOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Winifred Lo et al.
CANCER IMMUNOLOGY RESEARCH (2019)
The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis
Sarah E. Taylor et al.
CANCER RESEARCH (2019)
Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages
Michael Behring et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2019)
Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015
Myong Cheol Lim et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Xiangbing Meng et al.
CANCERS (2018)
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
Michiel Remmerie et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Charles-Andre Philip et al.
BMC CANCER (2017)
Targeting fibroblast growth factor pathways in endometrial cancer
Boris Winterhoff et al.
CURRENT PROBLEMS IN CANCER (2017)
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
Antonio Colaprico et al.
NUCLEIC ACIDS RESEARCH (2016)
ARID1A gene mutation in ovarian and endometrial cancers
Takashi Takeda et al.
ONCOLOGY REPORTS (2016)
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth
Dorien Haesen et al.
CANCER RESEARCH (2016)
Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis
Jun Cao et al.
MEDICINE (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
PPP2R1A mutations are common in the serous type of endometrial cancer
Deepak C. Nagendra et al.
MOLECULAR CARCINOGENESIS (2012)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Human Cancer-Associated Mutations in the Aα Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in Aα Knock-In and Knockout Mice
Ralf Ruediger et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
A Phase 2 Study of the Oral Mammalian Target of Rapamycin Inhibitor, Everolimus, in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
CANCER (2010)
Wnt signal transduction pathways
Yuko Komiya et al.
Organogenesis (2010)
Molecular Profiling of Endometrial Malignancies
Norasate Samarnthai et al.
OBSTETRICS AND GYNECOLOGY INTERNATIONAL (2010)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Uhn Soo Cho et al.
NATURE (2007)
Stage IIIC endometrioid corpus cancer includes distinct subgroups
A Mariani et al.
GYNECOLOGIC ONCOLOGY (2002)
Share Paper
